<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 12.7: Next-Generation Probiotics: Beyond Bifido and Lacto</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - GREEN theme for Gut Health */
        .module-header {
            background: linear-gradient(135deg, #059669 0%, #10B981 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #059669;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #059669;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #059669;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f0fdf4;
            border: 2px solid #10B981;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #059669;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #059669;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #111;
            margin: 30px 0 15px 0;
            font-weight: 600;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #059669 0%, #10B981 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
            letter-spacing: 0.5px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #10B981, #059669);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            color: white;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #059669 0%, #10B981 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Data Table */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
        }

        th {
            background: #f1f8f1;
            color: #059669;
            font-weight: 600;
            text-align: left;
            padding: 15px;
            border-bottom: 2px solid #e0e0e0;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #eee;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #059669;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            font-family: inherit;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #2e7d32;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #f0f8f0;
            border-radius: 8px;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f3f4f6;
            padding: 25px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .references-box {
            margin-top: 40px;
            padding-top: 25px;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            color: #888;
            font-size: 13px;
        }

        /* Utility */
        .stat-highlight {
            color: #059669;
            font-weight: 700;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="https://accredipro.com/wp-content/uploads/2023/05/AccrediPro-Logo-Standard.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 12: Advanced Therapeutic Interventions</p>
            <h1 class="lesson-title">Lesson 12.7: Next-Generation Probiotics: Beyond Bifido and Lacto</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Level: Advanced Practitioner</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Paradigm Shift in Probiotics</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Akkermansia muciniphila</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Faecalibacterium prausnitzii</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Christensenellaceae & Longevity</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Psychobiotics & Postbiotics</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Clinical Safety & Regulation</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Distinguish between conventional "Big Two" probiotics and Next-Generation Probiotics (NGPs).</li>
                <li>Evaluate the clinical evidence for <i>Akkermansia muciniphila</i> in metabolic health.</li>
                <li>Understand the anti-inflammatory mechanisms of <i>Faecalibacterium prausnitzii</i>.</li>
                <li>Analyze the role of <i>Christensenellaceae</i> in lean phenotypes and biological aging.</li>
                <li>Assess the regulatory landscape and safety profiles of emerging microbial therapeutics.</li>
            </ul>
        </div>

        <h2 id="section1">1. The Paradigm Shift in Probiotics</h2>
        <p>For decades, the probiotic market was dominated by two genera: <span class="highlight">Lactobacillus</span> and <span class="highlight">Bifidobacterium</span>. While these "Big Two" offer significant benefits for acute issues like antibiotic-associated diarrhea and general immune support, they represent only a tiny fraction of the human microbiome's functional diversity. As we move into the era of precision gut health, the focus is shifting toward <span class="highlight">Next-Generation Probiotics (NGPs)</span>â€”commensal organisms that naturally dominate the healthy human gut but are notoriously difficult to culture due to their strict anaerobic requirements.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">90%</div>
                    <div class="stat-label">Of Gut Bacteria are Anaerobic</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">3.5%</div>
                    <div class="stat-label">Avg. Akkermansia in Healthy Adults</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">10x</div>
                    <div class="stat-label">Potency of NGPs vs Conventional</div>
                </div>
            </div>
        </div>

        <p>Unlike conventional probiotics, which are often "transient" (meaning they don't colonize long-term), NGPs are often <span class="highlight">keystone species</span>. They perform critical ecological roles, such as maintaining the intestinal barrier, modulating the host's metabolism, and producing high concentrations of butyrate. In this lesson, we explore the therapeutic potential of these emerging giants and how they integrate into <b>The Method</b> for advanced client cases.</p>

        <h2 id="section2">2. Akkermansia muciniphila: The Metabolic Sentinel</h2>
        <p><i>Akkermansia muciniphila</i> is perhaps the most famous NGP. Residing in the mucus layer of the large intestine, it accounts for roughly 1-5% of the total fecal microbiota in healthy individuals. Its primary "job" is to degrade mucin, which sounds counterintuitive but is actually vital for gut health. By consuming old mucus, <i>Akkermansia</i> stimulates goblet cells to produce fresh mucus, effectively <span class="highlight">rejuvenating the intestinal barrier</span>.</p>

        <h3>Metabolic Impact and GLP-1</h3>
        <p>A landmark 2019 study published in <i>Nature Medicine</i> demonstrated that supplementation with <i>Akkermansia</i> (specifically a pasteurized form) significantly improved metabolic markers in overweight volunteers. The mechanisms include:</p>
        <ul>
            <li><b>Amuc_1100:</b> A specific protein on the outer membrane of <i>Akkermansia</i> that interacts with Toll-like receptor 2 (TLR2), strengthening tight junctions.</li>
            <li><b>GLP-1 Stimulation:</b> <i>Akkermansia</i> promotes the secretion of Glucagon-like peptide-1, the same hormone targeted by modern weight-loss medications, which improves insulin sensitivity and reduces systemic inflammation.</li>
        </ul>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: Metabolic Syndrome & Akkermansia</p>
                    <p class="subtitle">Clinical Application of NGP Supplementation</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">M</div>
                    <div class="patient-info">
                        <h4>Marcus, 52</h4>
                        <p>BMI: 31.4 | Prediabetic (HbA1c 5.9%) | High CRP (3.2 mg/L)</p>
                    </div>
                </div>
                <p><b>Intervention:</b> Following 12 weeks of calorie-restricted diet (The Method: Nutrition Phase), Marcus was plateaued. We introduced 10<sup>10</sup> AFU of pasteurized <i>Akkermansia muciniphila</i> daily.</p>
                <p><b>Outcomes:</b>
                    <ul>
                        <li><b>Insulin Sensitivity:</b> HbA1c dropped to 5.4% within 3 months.</li>
                        <li><b>Inflammation:</b> CRP reduced to 1.1 mg/L, indicating a resolution of metabolic endotoxemia.</li>
                        <li><b>Weight Loss:</b> Marcus lost an additional 4.5kg without further caloric restriction.</li>
                    </ul>
                </p>
            </div>
        </div>

        <h2 id="section3">3. Faecalibacterium prausnitzii: The Anti-Inflammatory Powerhouse</h2>
        <p>If <i>Akkermansia</i> is the guardian of the barrier, <span class="highlight">Faecalibacterium prausnitzii</span> is the master of anti-inflammation. It is one of the most abundant bacteria in the healthy human colon, often making up 5-15% of the total population. A <span class="highlight">low abundance</span> of <i>F. prausnitzii</i> is a consistent biomarker for Crohn's disease, Ulcerative Colitis, and IBS.</p>

        <p>The primary mechanism of <i>F. prausnitzii</i> is the production of <b>Butyrate</b> via the fermentation of dietary fiber. However, it goes beyond just SCFA production. It secretes a protein called <b>MAM</b> (Microbial Anti-inflammatory Molecule), which inhibits the NF-ÎºB pathwayâ€”the primary "on switch" for inflammation in the gut lining.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>Conventional (e.g., L. acidophilus)</th>
                        <th>Next-Gen (e.g., F. prausnitzii)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><b>Origin</b></td>
                        <td>Fermented foods/Dairy</td>
                        <td>Human Gut Commensal</td>
                    </tr>
                    <tr>
                        <td><b>Oxygen Tolerance</b></td>
                        <td>Facultative Anaerobe (Tolerates O2)</td>
                        <td>Strict Anaerobe (Killed by O2)</td>
                    </tr>
                    <tr>
                        <td><b>Colonization</b></td>
                        <td>Transient (Temporary)</td>
                        <td>Autochthonous (Permanent)</td>
                    </tr>
                    <tr>
                        <td><b>Primary Function</b></td>
                        <td>Lactic Acid / Competitive Inhibition</td>
                        <td>Butyrate / Metabolic Signaling</td>
                    </tr>
                    <tr>
                        <td><b>Clinical Target</b></td>
                        <td>General Wellness / Diarrhea</td>
                        <td>IBD / Metabolic Syndrome / Obesity</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section4">4. Christensenellaceae: The "Lean" Microbe</h2>
        <p>The <i>Christensenellaceae</i> family has recently emerged as a highly heritable and desirable component of the microbiome. Research involving twin studies (n=416) found that this family is the most heritable taxon and is highly enriched in individuals with a <span class="highlight">low BMI (lean phenotype)</span>.</p>

        <p>Beyond weight management, <i>Christensenellaceae</i> is strongly associated with <span class="highlight">longevity</span>. Centenarian studies consistently show higher levels of these bacteria compared to younger adults, suggesting they play a role in healthy aging by maintaining gut homeostasis and preventing "inflammaging." While not yet available as a commercial supplement, practitioners can encourage its growth through high-polyphenol diets and specific prebiotic fibers like galactooligosaccharides (GOS).</p>

        <h2 id="section5">5. Psychobiotics & Postbiotics: The New Frontier</h2>
        <p>As discussed in previous modules on the Gut-Brain Axis, <span class="highlight">Psychobiotics</span> are probiotics that, when ingested in adequate amounts, produce a health benefit in patients suffering from psychiatric illness. However, the next generation is moving toward <span class="highlight">Postbiotics</span>â€”non-viable bacterial products or metabolic byproducts that provide a physiological benefit.</p>

        <h3>Key Emerging Strains:</h3>
        <ul>
            <li><b>Lactobacillus plantarum PS128:</b> Shown in clinical trials to modulate dopamine and serotonin levels in the prefrontal cortex, aiding in the management of Parkinsonâ€™s and Autism Spectrum Disorder (ASD).</li>
            <li><b>Bifidobacterium longum 1714:</b> Demonstrated to reduce cortisol levels and improve cognitive performance under acute stress.</li>
            <li><b>Postbiotic Advantages:</b> Because postbiotics are non-living, they have a longer shelf life, do not require refrigeration, and carry zero risk of translocation (infection) in immunocompromised clients.</li>
        </ul>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ§ </div>
                <div>
                    <p class="box-label">Case Study: Psychobiotic Intervention for Anxiety</p>
                    <p class="subtitle">Addressing the Vagus Nerve via Microbial Signaling</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">S</div>
                    <div class="patient-info">
                        <h4>Sarah, 29</h4>
                        <p>Generalized Anxiety Disorder | Stress-Induced IBS-D</p>
                    </div>
                </div>
                <p><b>Intervention:</b> Sarah was already on a Mediterranean-style diet but struggled with "morning anxiety" and urgency. We added a targeted psychobiotic (<i>B. longum</i> 1714) for 8 weeks.</p>
                <p><b>Outcomes:</b>
                    <ul>
                        <li><b>Stress Resilience:</b> Sarah reported a 40% reduction in perceived stress scores (PSS).</li>
                        <li><b>Bowel Habits:</b> IBS-D symptoms resolved, likely due to reduced vagal hyper-excitability.</li>
                        <li><b>Mechanism:</b> Follow-up salivary cortisol tests showed a normalized diurnal rhythm.</li>
                    </ul>
                </p>
            </div>
        </div>

        <h2 id="section6">6. Clinical Safety & Regulatory Status</h2>
        <p>The regulatory path for NGPs is complex. In the US, the FDA classifies many as "Live Biotherapeutic Products" (LBPs) if they are intended for disease treatment, requiring rigorous Phase I-III clinical trials. In the EU, the EFSA evaluates them under the "Novel Food" category.</p>

        <p><b>Practitioner Note on Safety:</b>
        While <i>Akkermansia</i> has achieved GRAS (Generally Recognized As Safe) status in the US, many other NGPs are still in the research phase. As a Gut Health Coach, your role is to:</p>
        <ol>
            <li>Monitor for "Novel Food" approvals before recommending specific NGP brands.</li>
            <li>Prioritize <span class="highlight">pasteurized versions</span> of NGPs when available, as they often show equal or superior metabolic benefits with lower risk profiles.</li>
            <li>Ensure the client has a "fiber foundation" (The Method: Step 2) before introducing these high-potency strains, as NGPs require specific substrates to thrive.</li>
        </ol>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of Next-Generation Probiotics</p>
            
            <div class="question-item">
                <p class="question-text">Why is <i>Akkermansia muciniphila</i> considered a "metabolic sentinel" despite consuming the gut's protective mucus layer?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Show Answer</button>
                <div class="answer-text">By degrading old mucus, it stimulates goblet cells to produce fresh, new mucus, which thickens and rejuvenates the intestinal barrier. It also produces the Amuc_1100 protein which strengthens tight junctions and promotes GLP-1 secretion.</div>
            </div>

            <div class="question-item">
                <p class="question-text">What is the primary clinical biomarker associated with low levels of <i>Faecalibacterium prausnitzii</i>?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Show Answer</button>
                <div class="answer-text">Low levels of <i>F. prausnitzii</i> are a consistent biomarker for Inflammatory Bowel Disease (IBD), specifically Crohn's disease and Ulcerative Colitis, due to its role in producing butyrate and the anti-inflammatory MAM molecule.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><b>Beyond Bifido:</b> Next-Generation Probiotics (NGPs) are human commensals that offer targeted, high-potency therapeutic effects compared to conventional strains.</li>
                <li><b>Akkermansia:</b> Use for metabolic syndrome, insulin resistance, and barrier repair. Pasteurized versions are clinically validated.</li>
                <li><b>F. prausnitzii:</b> The "gold standard" anti-inflammatory microbe, critical for IBD and butyrate production.</li>
                <li><b>Postbiotics:</b> Non-viable microbes are an emerging, safe alternative for sensitive or immunocompromised clients.</li>
                <li><b>The Method:</b> Always ensure adequate prebiotic substrate (fiber/polyphenols) is present to support NGP colonization and function.</li>
            </ul>
        </div>

        <div class="references-box">
            <p class="box-label">References & Further Reading</p>
            <ul>
                <li>Depommier et al. (2019). "Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study." <i>Nature Medicine</i>.</li>
                <li>Miquel et al. (2013). "Faecalibacterium prausnitzii and human intestinal health." <i>Current Opinion in Microbiology</i>.</li>
                <li>Goodrich et al. (2014). "Human Genetics Shape the Gut Microbiome." <i>Cell</i>. (On Christensenellaceae heritability).</li>
                <li>Cani et al. (2022). "Akkermansia muciniphila: from discovery to therapeutic applications." <i>Frontiers in Microbiology</i>.</li>
                <li>Sokol et al. (2008). "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients." <i>PNAS</i>.</li>
                <li>Salminen et al. (2021). "The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics." <i>Nature Reviews Gastroenterology & Hepatology</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="https://accredipro.com/wp-content/uploads/2023/05/AccrediPro-Logo-Standard.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy | Gut Health & Microbiome Coach Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>